Renal toxicity. Drug- and heavy-metal-induced tubulo-interstitial and tubular conditions
Conditions
Interventions
Intervention 1: Intervention group: Includes 30 patients, until gentamicin is prescribed, pentoxifylline sustained release 400 mg tablet (Farabi Pharmaceutical Company) is given orally three times a d
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age higher than 18 years Receiving intravenous or intramuscular gentamicin for at least 1 week No confirmed acute or chronic kidney injury Do not take gentamicin intravenously or intramuscularly during the past 14 days Do not take pentoxifylline orally during the past week No confirmed history of allergic reactions to pentoxifylline Informed consent form
Exclusion criteria
Exclusion criteria: Patient with hemodynamic instability Concomitant use of medicines or antioxidant compounds such as vitamin C, vitamin E, or vitamin A Concomitant use of medications with high renal toxicity No tolerant of oral medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gentamicin nephrotoxicity is defined by either a rise in the plasma creatinine concentration of more than 0.5 to 1 mg/dL. Timepoint: Serum creatinine is measured before starting gentamicin treatment (day 0) and days 1, 3, 5, and 7 of gentamicin treatment. Method of measurement: Measurement of serum creatinine is done by using an autoanalyzer device.;Hypokalemic electrolyte disorder (serum level potassium below 3 mEq/L). Timepoint: Serum potassium level are determined before starting gentamicin treatment (day 0) and days 1, 3, 5, and 7 of gentamicin treatment. Method of measurement: Measurement of Serum potassium level is done by using an autoanalyzer device.;Hypomagnesemia electrolyte disorder (serum magnesium level below 1.2 mEq/L). Timepoint: Serum magnesium level are determined before starting gentamicin treatment (day 0) and days 1, 3, 5, and 7 of gentamicin treatment. Method of measurement: Measurement of Serum magnesium level is done by using an autoanalyzer device. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum level of TNF-a. Timepoint: Serum level of TNF-a is measured before starting gentamicin treatment (day 0) and day 7 of gentamicin treatment. Method of measurement: Measurement of TNF-a is done by the ELISA method.;Serum level of malondialdehyde. Timepoint: Serum level of malondialdehyde is measured before starting gentamicin treatment (day 0) and day 7 of gentamicin treatment. Method of measurement: Measurement of malondialdehyde is done by the ELISA method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactIman Karimzadeh
Shiraz University of Medical Sciences
Outcome results
None listed